All In Biotech

Drug Trial Radar · NCT02460224

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies

Last checked: Nov 20, 2026Latest source record: Feb 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

490

Actual

Start

Jun 17, 2015

Primary completion

Dec 31, 2020

Study completion Dec 31, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 2, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation (phase 1) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001, and a dose expansion (phase 2) which characterized treatment of LAG525 in combination with PDR001 at the MTD or RP2D.

Conditions

  • Advanced Solid Tumors

Interventions

  • LAG525Drug

    LAG525 was administered via intravenous (i.v.) infusion

  • PDR001Drug

    PDR001 was administered via i.v. infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: 15 days for single-agent LAG525 arms and 30 days for the combination LAG525 + PDR001 arms
  2. Phase 2: Overall Response Rate (ORR) Per RECIST 1.1Time frame: From start of treatment until end of treatment, assessed up to 2.6 years

Locations

24 sites in 12 countries. Site status is shown where the registry gives one.

  • Columbia University Medical Center SC LAG X2101C

    New York, New York

  • Memorial Sloan Kettering Cancer Center SC

    New York, New York

  • Duke Clinical Research Institute SC

    Durham, North Carolina

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Cancer Therapy and Research Center UT Health Science Center CTRC 2

    San Antonio, Texas

  • Huntsman Cancer Institute Huntsman Cancer Institute

    Salt Lake City, Utah

  • Novartis Investigative Site

    Westmead, New South Wales, Australia

  • Novartis Investigative Site

    Heidelberg, Victoria, Australia

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Edmonton, Alberta, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Saint-Herblain Cédex, France

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Würzburg, Germany

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Modena, MO, Italy

  • Novartis Investigative Site

    Fukuoka, Fukuoka, Japan

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.